Αρχική World News The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That Has...

The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That Has Educated Us

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As that tool reaches the milestone of 100,000 care plans created, OncoLink’s Editor in Chief Christine Hill-Kayser, MD, explains that we have also learned a lot from the users of the care plan.

OncoLink launched the OncoLife Survivorship Care Plan in 2007.  We are a group of healthcare providers with a mission: to provide comprehensive, accessible, and accurate information for people experiencing cancer – as patients, caregivers, and, of course, survivors. The intention of OncoLife has always been to provide customized information and recommendations for people at any phase of the survivorship journey – from the moment of diagnosis, until years after active treatment.  In order to build our first version, we scoured the existing literature and professional group recommendations.  Fourteen years ago, and even now, the lack of data in many areas of survivorship caused us frustration.  We consulted experts where data were not available, and we told our users about unknowns in the literature.  Since that time, we have had the privilege of increasing knowledge about some of those unknowns through research and publication. It is thanks to our users – cancer survivors and those who care for them – that we have been able to do this. We are infinitely grateful.

In the beginning, our research focused on how we could best provide an internet-based care plan.

  • What were the best ways to write content?
  • How could we build the care plan?
  • How could we make it available to users far and wide?
  • How would it be used, not only by cancer survivors in areas of great advocacy such as breast cancer, but by groups with less public visibility and fewer people – such as lung cancer survivors?
  • Would older people, potentially with less Internet access, use it?
  • Would healthcare providers use it?
  • Could we translate it into other languages?

The answers, over and over, were “YES!”  People would use it. We learned, however, that different groups had different needs, and that young, white, highly educated, women were the most likely users.  Based on these findings, we launched a version of the care plan specifically tailored for nurses and other healthcare providers to use to provide care plans for patients. This allowed access for populations less likely to create care plans for themselves.  We received diverse feedback regarding information volume – many people wanted more and more information; however, others found large amounts of information overwhelming. We again added choice to the care plan – users can receive a long, comprehensive document, or can choose a more concise document that simply lists “key takeaways.” A version of the care plan is available in Spanish.  We still struggle with ensuring that all populations have access to valuable information – but we have made significant progress.

Five years after our initial launch, we were able to begin learning at a more granular level about different populations of cancer survivors and their unique needs.  We began to incorporate the individual experience – in the form of patient reported outcomes – into care plans.  We asked survivors what bothersome late or long-term effects they might be experiencing, and their reports drove the prioritization of their care plans. We learned that fatigue, sexual changes, and neurocognitive changes are experienced by huge numbers of survivors, and are frequently of highest priority to survivors, although they are less frequently addressed by healthcare providers than many other late effects.  We learned that breast cancer survivors themselves are much more likely to be dissatisfied with the appearance of their breasts after treatment than providers report.  We learned that survivors who have chronic cancers – which are treatable if not curable – experience more symptoms than their counterparts whose cancers are thought to be curable. Despite this, survivors with chronic cancers are less likely to receive survivorship information and less likely to have primary care providers. We learned that <15% of cancer survivors receive dedicated survivorship information across our country, and that significant disparities remain in this distribution.

The news is not all bleak! We also learned that people who use our care plan get new information from it, and most of them feel that this information is useful and would recommend the care plan to other survivors. We learned that most users feel that the care plan improves communication with healthcare teams and that it prompts healthy behavior and lifestyle changes. We have investigated and implemented methods of embedding the care plan into health system electronic medical records to facilitate care planning for all survivors. Over time, our care plan has evolved through 11 versions – each with the goal of better providing access and information to groups of cancer survivors and caregivers who need it.

Our tool remains free and publicly accessible, and our mission is unchanged. We are grateful to our users, who have allowed us to grow and change in order to better achieve that mission. We’ve been at this for nearly 15 years, but we are nowhere near done. We look forward to the next decades of research and growth to support the cancer survivorship community with great anticipation and excitement.


Christine Hill-Kayser, MD is the Editor in Chief of Oncolink, Chief of the Pediatric Radiation Oncology Service and Associate Professor of Radiation Oncology at the University of Pennsylvania and Children’s Hospital of Philadelphia.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...